Resources & Guides

Side-by-side comparison of Oak, Gala, ShedRx, and YourEra — pricing, legitimacy, and which ones are worth it

Real monthly costs from $129-297/mo — hidden fees, dose-based pricing traps, and brand-name comparison

Compare platforms for sermorelin, NAD+, PT-141, and GLP-1 microdosing — from $99/mo

Protein targets, resistance training, creatine, and monitoring — a 2025 study limited muscle loss to just 3%

Why it happens (telogen effluvium), timeline, prevention strategies, and prescription treatment from $25/mo

NF-kB suppression, cytokine reduction, M2 macrophage polarization — the mechanisms behind benefits across 10+ conditions

How peptides work, evidence tiers, peptides vs steroids, safety, and research peptides vs prescription

The longevity molecule — what the science supports, delivery formats, and telehealth from $116/mo

Stimulate your own GH naturally — injection, tablet, or oral lozenge from $99/mo. Safer & cheaper than HGH

Minimum effective dosing for gentler weight loss — who it's for and how protocols work, from $116/mo

HbA1c reduced 1.5-2.0%, cardiovascular death cut 26%. The foundational use case

SELECT trial: 20% MACE reduction. FDA-approved for cardiovascular risk reduction

Zepbound: first FDA-approved drug for OSA. Only 4% needed to start CPAP vs 22% without

FDA-approved for MASH with fibrosis. Reduces hepatic fat, inflammation, and fibrosis

FDA-approved for diabetic CKD. FLOW trial: slowed progression to dialysis

Tirzepatide reduced diabetes progression ~94%. 84% reverted to normal blood sugar

GLP-1s improve HOMA-IR by 30-50%. The upstream driver of most metabolic disease

Tirzepatide lowers systolic BP 7-8 mmHg. Every 5 mmHg cuts CV risk ~10%

Triglycerides down 15-20%, CRP down ~40%. Complements but doesn't replace statins

Obesity doubles gout risk. GLP-1 users show fewer flares — but watch the early rapid-loss caveat

86% showed nerve improvement within 1 month. Potential breakthrough for diabetic nerve damage

39% reduction in non-fatal stroke (SUSTAIN 6). Addresses multiple risk factors simultaneously

41.7-point pain score reduction. Weight relief + direct anti-inflammatory effects in joints

34% fewer CV events, 74% lower mortality. Safe with immunosuppressants

TNF-alpha and IL-17 reduction. Improved PASI scores, works alongside biologics

Fewer hospitalizations, no flare signal. The GLP-2 gut-healing connection

14-18% lower respiratory disease risk. GLP-1 receptors in lung tissue

Lancet Psychiatry 2026: lower risk of worsening mental illness. Neuroprotective mechanisms

40-70% lower risk in observational studies — but Phase 3 trials failed for existing disease

Cut migraine days nearly in half (20→11/month) — independent of weight loss

Lancet 2026 RCT: semaglutide significantly reduces heavy drinking days and cravings

40-60% lower risk in observational studies. GLP-1 receptors on dopamine neurons

GLP-1s suppress food-reward dopamine signaling — binge episodes reduced 40-70%

Restored menstrual cycles in ~12 weeks. Insulin sensitization + androgen reduction

HRT + GLP-1 synergy: 16% body weight loss. Visceral fat redistribution

GLP-1s restore ovulation in PCOS — leading to unexpected pregnancies. When to stop before conception

Mixed short-term effects, net positive long-term. PT-141 and tadalafil options

UC San Diego 2026: semaglutide reduced biological age by 3.1 years in 32 weeks

17-41% lower cancer risk across multiple large 2025-2026 studies. Mechanisms beyond weight loss

No fracture increase in 17,600+ patients. GLP-1 receptors on bone-forming cells